Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
FREMONT, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society
Oral presentation of the safety and efficacy of Qtrypta TM in a long-term safety study for the acute treatment of migraine. Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies.
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 1:30 p.m. PT today FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019 , as well as recent business
View HTML
Toggle Summary Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache
FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to initiate a Phase
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update
FREMONT, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019
View HTML
Toggle Summary Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting
Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the Effectiveness of Qtrypta in Treating Migraines FREMONT, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of
View HTML
Toggle Summary Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference
FREMONT, Calif. , July 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis , senior vice president of operations at Zosano Pharma , will be presenting a keynote speech entitled, “A Novel Intracutaneous
View HTML
Toggle Summary Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting
FREMONT, Calif. , July 01, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following
View HTML
Toggle Summary Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activities NDA planned for Q4 2019 FREMONT, Calif. , June 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2019 Financial Results
Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology Conference call scheduled for 1:30 pm PT today FREMONT, Calif.
View HTML